September 9, 2022 08:14 AM EDTUpdated 10:00 AM
R&D

#ES­MO22: Da­ta on two key check­point fail­ures high­light Mer­ck­'s dom­i­nance in ad­ju­vant set­ting

John Carroll

Editor & Founder

PARIS — Mer­ck came in­to ES­MO con­fi­dent that it reigned supreme in the ad­ju­vant set­ting for re­nal cell car­ci­no­ma — the new fron­tier for check­point in­hibitors. It …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times